LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

47.94 1.31

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

46.43

Massimo

49.05

Metriche Chiave
By Trading Economics
Entrata	-14M -130M
Vendite	-888K 143K
Margine di Profitto	-90,972.727
Dipendenti	437
EBITDA	33K -129M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+68.78% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	462M 4.5B
Apertura precedente	46.63
Chiusura precedente	47.94

Notizie sul Sentiment di mercato

By Acuity

50%

52 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

30.39 / 33.46 Supporto e resistenza

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 dic 2025, 22:13 UTC

Utili

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 dic 2025, 21:40 UTC

Utili

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 dic 2025, 18:51 UTC

Acquisizioni, Fusioni, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 dic 2025, 16:57 UTC

I principali Market Mover

Clear Secure Rises on Medicare Identity Verification Contract

9 dic 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 dic 2025, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 dic 2025, 23:45 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 dic 2025, 23:44 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 dic 2025, 23:43 UTC

Acquisizioni, Fusioni, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 dic 2025, 23:35 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 dic 2025, 22:42 UTC

Utili

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

9 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 21:48 UTC

Discorsi di Mercato

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 dic 2025, 21:36 UTC

Utili

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 dic 2025, 20:28 UTC

Discorsi di Mercato

Oil Futures Decline for Second Straight Session -- Market Talk

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 dic 2025, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 dic 2025, 20:26 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 dic 2025, 20:21 UTC

Discorsi di Mercato

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 dic 2025, 19:52 UTC

Utili

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 dic 2025, 19:17 UTC

Utili

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 dic 2025, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 dic 2025, 17:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 dic 2025, 17:11 UTC

Utili

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

68.78% in crescita

Previsioni per 12 mesi

Media 80 USD 68.78%

Alto 108 USD

Basso 45 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 15 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

52 / 374 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.